Clobetasone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Clobetasone: From Topical Corticosteroid Therapy to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Clobetasone is a topical glucocorticoid receptor agonist used for its anti-inflammatory effects on skin conditions; no original indication or TFDA licensing record is currently on file for this compound in Taiwan. The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma, but this is currently supported by 0 clinical trials and 0 publications — the signal rests entirely on mechanistic plausibility and the model’s prediction score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text on file (drug not marketed in Taiwan) |
| Predicted New Indication | Primary Cutaneous T-Cell Lymphoma |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 (mechanism-based only; no direct trials or literature) |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, drug-specific mechanism-of-action data for Clobetasone is not currently available in our DrugBank extract (flagged as a High-severity data gap). Based on the information available from the repurposing analysis, Clobetasone is a topical glucocorticoid receptor agonist with anti-inflammatory and lymphocyte apoptosis-inducing activity — properties shared by the broader corticosteroid class.
Topical corticosteroids are already recognized, class-level adjunctive or first-line agents in early-stage cutaneous T-cell lymphoma (e.g., mycosis fungoides), and the administration route (topical) matches the lesion site (skin) for this prediction. This route/site alignment is the main reason the mechanistic rationale is rated moderate-to-high plausibility.
However, this rationale is class-level, not drug-specific: our search of ClinicalTrials.gov, ICTRP, and PubMed returned zero Clobetasone-specific trials or publications for this indication. The prediction should therefore be read as a research hypothesis generated by mechanistic analogy and the TxGNN score, not as evidence of demonstrated efficacy for Clobetasone itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Clobetasone currently has no TFDA marketing authorization on file (market status: Not marketed, 0 registrations). No dosage form, brand name, or approved indication text is available for Taiwan.
Safety Considerations
Please refer to the package insert for safety information. TFDA label warnings/contraindications and drug-drug interaction data are not currently available for Clobetasone (data gap DG001, Blocking severity) — this must be resolved before any safety evaluation (Stage S1) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by mechanistic analogy and a TxGNN score, with zero drug-specific clinical trials or literature, no Taiwan market presence, and a Blocking-severity gap in TFDA safety data — insufficient basis to advance past the research-question stage.
To proceed, the following is needed:
- TFDA package insert (warnings, contraindications) — resolves blocking data gap DG001
- Confirmed mechanism-of-action data via DrugBank API — resolves data gap DG002
- Targeted literature/trial search using expanded synonyms (e.g., “topical corticosteroid,” “clobetasone butyrate”) to rule out indexing gaps rather than true absence of evidence
- Assessment of systemic absorption/HPA-axis suppression risk from topical use, particularly given the model separately flagged “adrenocortical insufficiency” as a candidate association that more likely reflects a known adverse effect than a therapeutic use — this should be reviewed as a safety signal, not repurposing potential
- If pursued, nonclinical (in vitro/in vivo) proof-of-concept data specific to Clobetasone in a cutaneous lymphoma model before any clinical evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.